- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
500,000 Women to be Offered Breast Cancer Drugs
Those most at risk should be eligible for preventative treatment to reduce the chances of it developing, NHS told. More than half a million women at risk of breast cancer should be offered drugs by the NHS for the first time to stop it developing, according to official health advice that could lead to a historic shift from treatment of the country's most common cancer to its prevention.
All women over 30 in England and Wales judged to be at moderate or high risk of breast cancer would be able to take one of two drugs to reduce their risk under the draft guideline drawn up by the National Institute for Health and Clinical Excellence (Nice).
Read the full story: http://bit.ly/Xzoldn
Source: Oncology Business Review
Bridging the Vaccination Gap: Insights on Global Immunization Challenges
July 30th 2024On this episode of Managed Care Cast, we speak with Jeffery A. Goad, PharmD, MPH, 2024-2025 president of the National Foundation for Infectious Diseases, on the recent report from the World Health Organization and UNICEF on public immunization rates, with national and global health implications.
Listen
5 Hot Health Care Topics in the Presidential Election
October 18th 2024A review of positions and track records of Vice President Kamala Harris and former President Donald Trump on reproductive health, the future of the Affordable Care Act, prescription drug costs, health care consolidation, and a proposed Medicare home health benefit.
Read More
Double Trouble: High-Deductible Plans Raise Maternity Care Costs Across 2 Calendar Years
June 27th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the June 2024 issue of The American Journal of Managed Care® about how annual high-deductible insurance plans increase maternity care costs when pregnancies cross 2 calendar years.
Listen
Methadone Associated With Lower Risk of Treatment Discontinuation in Opioid Use Disorder
October 17th 2024Amidst ambiguous international guidelines for first-line treatment of opioid use disorder, a new population-based study sheds light on the benefits of methadone vs buprenorphine/naloxone for holding off treatment discontinuation.
Read More
